Trial Profile

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Axitinib (Primary)
Indications Glioblastoma; Gliosarcoma
Focus Therapeutic Use
Acronyms GliAvAx

Most Recent Events

04 Jun 2019 Results assessing the outcome of patients with recurrent glioblastoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
22 Jan 2019 Status changed from recruiting to completed.
05 Jun 2018 Results (as of Jan 2018, n=32, 280 treatment weeks in Cohort A and B) assessing safety of axitinib plus avelumab in patients with recurrent glioblastoma, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com